Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with China’s Hansoh Pharmaceuticals Group Company to acquire exclusive clinical ...

AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at GPR75, a protective gene identified by scientists at the Regeneron ...

Regeneron acquires rights to HS-20094, a promising obesity treatment from Hansoh Pharma, enhancing its metabolic programs. Quiver AI Summary. Regeneron Pharmaceuticals has entered a strategic ...

Key complementary asset enables synergy and flexibility across Regeneron’s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities and long ...

TARRYTOWN, N.Y. - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a prominent biotechnology company with annual revenue of $14.1 billion and strong financial health according to InvestingPro ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone ... Regeneron's Obesity Trial With Novo Nordisk's Wegovy ... Sanofi Stock Falls After Uneven Smoker’s Lung Drug Data.

Semaglutide and similar GLP-1 drugs have proven to be highly effective obesity and type 2 diabetes treatments. But like every drug, they have their possible trade-offs, including muscle loss.

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China Phase 2 data suggest potentially ...